Nurix Therapeutics Inc (NRIX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.69B
Last updated: Nov 17, 2026 at 11:06 AM ET
Nurix Therapeutics Inc (NRIX) Earnings: Report Dates and Results
Nurix Therapeutics (NRIX) is expected to report earnings on Jan 26, 2027. In the quarter ended Aug 31, 2026, Nurix Therapeutics reported EPS of $4.73, above the -$0.56 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NRIX has an expected report date of Jan 26, 2027.
Earnings History
Of the 25 quarters below that had an estimate, NRIX beat 12 and missed 13. Revenue for the quarter ended Aug 31, 2026 was $673.06M, up 8430.5% from $7.89M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | $4.73 | -$0.56 | N/A | +944.64% | Beat | N/A | 3 | 2 up, 0 down | Oct 12, 2026 | $673.06M |
| May 31, 2026 | -$0.81 | -$0.73 | -$0.86 - -$0.50 | -10.96% | Miss | N/A | 14 | 1 up, 1 down | Jul 9, 2026 | $9.04M |
| Feb 28, 2026 | -$0.79 | -$0.83 | -$0.89 - -$0.65 | +4.76% | Beat | N/A | 12 | 5 up, 1 down | Apr 8, 2026 | $6.25M |
| Nov 30, 2025 | -$0.82 | -$0.92 | -$1.15 - -$0.72 | +10.87% | Beat | N/A | 12 | 0 up, 0 down | Jan 28, 2026 | $13.58M |
| Aug 31, 2025 | -$1.03 | -$0.85 | -$0.99 - -$0.68 | -21.18% | Miss | N/A | 15 | 5 up, 10 down | Oct 9, 2025 | $7.89M |
| May 31, 2025 | -$0.52 | -$0.74 | -$0.96 - -$0.60 | +29.73% | Beat | N/A | 15 | 1 up, 0 down | Jul 9, 2025 | $44.06M |
| Feb 28, 2025 | -$0.67 | -$0.76 | -$0.89 - -$0.58 | +11.84% | Beat | N/A | 13 | 0 up, 6 down | Apr 8, 2025 | $18.45M |
| Nov 30, 2024 | -$0.75 | -$0.67 | -$0.89 - -$0.54 | -12.12% | Miss | N/A | 13 | 7 up, 2 down | Jan 28, 2025 | $13.28M |
| Aug 31, 2024 | -$0.67 | -$0.68 | -$0.86 - -$0.60 | +1.47% | Beat | N/A | 12 | 0 up, 0 down | Oct 11, 2024 | $12.59M |
| May 31, 2024 | -$0.71 | -$0.63 | -$0.85 - -$0.40 | -12.70% | Miss | N/A | 12 | 3 up, 0 down | Jul 11, 2024 | $12.09M |
| Feb 29, 2024 | -$0.76 | -$0.80 | -$0.95 - -$0.64 | +5.00% | Beat | N/A | 10 | 0 up, 0 down | Apr 10, 2024 | $16.59M |
| Nov 30, 2023 | -$0.77 | -$0.50 | -$1.02 - $0.35 | -54.00% | Miss | N/A | 11 | 1 up, 0 down | Feb 15, 2024 | $15.16M |
| Aug 31, 2023 | -$0.68 | -$0.74 | N/A | +8.11% | Beat | N/A | 11 | 0 up, 0 down | Oct 12, 2023 | $18.47M |
| May 31, 2023 | -$0.45 | -$0.57 | -$0.91 - -$0.39 | +21.05% | Beat | N/A | 10 | 0 up, 0 down | Jul 13, 2023 | $30.68M |
| Feb 28, 2023 | -$0.75 | -$0.87 | -$1.00 - -$0.76 | +13.79% | Beat | N/A | 10 | 0 up, 0 down | Apr 13, 2023 | $12.69M |
| Nov 30, 2022 | -$0.87 | -$0.79 | -$0.98 - -$0.29 | -10.13% | Miss | N/A | 9 | 0 up, 0 down | Feb 9, 2023 | $6.78M |
| Aug 31, 2022 | -$0.90 | -$0.95 | -$1.14 - -$0.87 | +5.26% | Beat | N/A | 9 | 0 up, 0 down | Oct 6, 2022 | $10.79M |
| May 31, 2022 | -$1.01 | -$0.99 | -$1.07 - -$0.94 | -2.02% | Miss | N/A | 8 | 0 up, 0 down | Jul 7, 2022 | $11.43M |
| Feb 28, 2022 | -$0.95 | -$0.89 | -$0.93 - -$0.77 | -6.74% | Miss | N/A | 7 | 0 up, 0 down | Apr 7, 2022 | $9.62M |
| Nov 30, 2021 | -$0.85 | -$0.69 | -$0.83 - -$0.37 | -23.19% | Miss | N/A | 8 | 0 up, 0 down | Jan 27, 2022 | $7.40M |
| Aug 31, 2021 | -$0.65 | -$0.62 | -$0.74 - -$0.47 | -4.84% | Miss | N/A | 6 | 0 up, 0 down | Oct 14, 2021 | $10.25M |
| May 31, 2021 | -$0.60 | -$0.56 | -$0.66 - -$0.39 | -7.14% | Miss | N/A | 6 | N/A | Jul 13, 2021 | $7.09M |
| Feb 28, 2021 | -$0.63 | -$0.45 | -$0.56 - -$0.34 | -40.00% | Miss | N/A | 5 | N/A | Apr 13, 2021 | $5.01M |
| Nov 30, 2020 | -$0.51 | -$0.54 | -$0.62 - -$0.42 | +5.56% | Beat | N/A | 5 | N/A | Feb 16, 2021 | $6.69M |
| Aug 31, 2020 | -$0.59 | -$0.45 | -$0.49 - -$0.31 | -31.11% | Miss | N/A | 4 | N/A | Oct 14, 2020 | $4.08M |
| May 31, 2020 | -$1.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jul 24, 2020 | $4.18M |
| Feb 29, 2020 | -$1.91 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 5, 2020 | $2.86M |
Annual EPS
| Fiscal year ended | EPS | Change |
|---|---|---|
| Aug 31, 2026 | -$16.01 | N/A |
| Nov 30, 2025 | -$3.04 | N/A |
| Nov 30, 2024 | -$2.89 | N/A |
| Nov 30, 2023 | -$2.65 | N/A |
| Nov 30, 2022 | -$3.73 | N/A |
| Nov 30, 2021 | -$2.73 | N/A |
| Nov 30, 2020 | -$4.10 | N/A |
Frequently Asked Questions About NRIX
When is Nurix Therapeutics's next earnings date?
Nurix Therapeutics's next earnings report is expected for Jan 26, 2027.
Did NRIX beat earnings estimates last quarter?
Yes. Nurix Therapeutics reported EPS of $4.73 for the quarter ended Aug 31, 2026, above the -$0.56 estimate, a 944.64% surprise.
What EPS do analysts expect from NRIX next quarter?
The consensus EPS estimate for Nurix Therapeutics for the quarter ending Nov 30, 2026 is -$0.50 from 16 analysts, with estimates from -$0.79 to $0.04.
How often does NRIX beat earnings estimates?
Nurix Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +119.70%.
NRIX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors